In the development of tumor electric field therapy, test and labeling for changes in tubulin are involved, for example, microtubule-labeled antibodiesare used to label microtubules, and changes in microtubule formation in tumor cells before and after electric field treatment are observed. In addition, a mitotic marker (phosphorylated histone 3) is also necessary to reflect the effect of the electric field on mitosis. For the study of the final therapeutic effect, the researchers need tumor cell marker antibodies and cell death marker antibodies (Annexin V) to show the specific killing efficiency of the electric field on cancer cells.